glp-1 obesity drug news today october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care Compound versions of GLP-1 drugs
Description
Mechanism: This effect is mediated by the activation of the vagus nerve and direct effects on gastric smooth muscle (Zheng et al., 2024)
In a study also published in The New England Journal of Medicine a few months later in June 2021, those taking 5mg lost about 7.8kg (about 17lbs), those with 10mg lost 10.3kg (about 22.7lbs), and those on 15mg lost 12.4kg (about 27lbs)
Congratulations to the regulatory, quality, SD&I, R&D, PMO, clinical affairs, and commercial teams and many more at DiaSorin and Luminex
This interesting finding, occurring without weight loss, is consistent with preclinical and clinical studies showing weight-independent effects of GLP-1R agonism on liver steatosis 51,52,53
The assessment of binge eating severity among obese persons
Clinical evidence for glp-1 receptor agonists in aAzheimers disease: A systematic review
